非布司他治疗效果如何呢？

It was first launched in the United States in March 2009 and is clinically used to treat hyperuricemia.

Febuxostat tablets are a commonly used drug for the treatment of gout. This drug has a very good effect on controlling hyperuricemia, and it can also be taken for a long time. As long as the dosage of the drug is used correctly, it can basically avoid adverse effects on people's health. So, what is the therapeutic effect of Febuxostat?

Animal experiments show that compared with allopurinol, febuxostat is 10 to 30 times more powerful.

The structure of febuxostat is a non-purine analogue, so it is selective in inhibiting xanthine oxidase and has little effect on other enzymes involved in purine and pyrimidine metabolism. Allopurinol is a purine analogue, which can affect the activity of other enzymes involved in purine and pyrimidine metabolism in the body, and is prone to some adverse reactions.

The specificity of the inhibitory effect of febuxostat can avoid these possible adverse reactions.

Febuxostat is completely absorbed after oral administration, with a bioavailability of about 85%, a peak time of about 1 hour, and a half-life of 5 to 8 hours. Food and antacids have no significant effect on the absorption of febuxostat.

Febuxostat can be used in combination with other drugs, such as colchicine (0.6 mg twice a day), certain non-steroidal anti-inflammatory drugs (naproxen, indomethacin, etc.), hydrochlorothiazide, warfarin, desimipramine, etc., without significant impact on the pharmacokinetics of the two, and no dose adjustment is required. However, it is currently not recommended to use febuxostat in combination with azathioprine and mercaptopurine because the latter two are metabolized by xanthine oxidase.

Research results show that long-term use of febuxostat can maintain long-term blood uric acid in most patients at ≤6.0 mg/dl. Mild to moderate impairment of renal function has no significant impact on the pharmacodynamics and pharmacokinetics of febuxostat. Therefore, the uric acid-lowering effect of febuxostat is no different from that of patients with normal renal function, and its safety is good.

In short, the uric acid-lowering effect is better than that of allopurinol without serious adverse reactions, and it has good clinical application prospects.